

# Material Safety Data Sheet ANSI Format

**Auralgan** 

Preparation Date 20-Aug-2007 Revision Date Not applicable Revision Number Not applicable

## 1. PRODUCT AND COMPANY IDENTIFICATION

Product NameAuralganCommon NameNot availableChemical NameNot applicableSynonymsAuralgan SolutionProduct UsePharmaceutical product

Classification Not available

**Supplier** Wyeth

P.O. Box 8299

Philadelphia, PA 19101 USA. Telephone: 1-610-688-4400

Emergency Telephone Number Chemtrec USA, Puerto Rico, Canada 1-800-424-9300

Chemtrec International 1-703-527-3887

## 2. HAZARDS IDENTIFICATION

**Emergency Overview** 

This contains an active pharmaceutical ingredient that can affect body functions; handle with caution.

Appearance Pharmaceutical LiquidPhysical State LiquidOdor Not available

Potential Physical Hazards None known.

**Potential Health Effects** 

**Eyes** May cause eye irritation. **Skin** May cause skin irritation.

**Inhalation** May cause irritation of respiratory tract.

Ingestion The most common effects may include nausea, vomiting, dizziness, dilated pupils, blueish skin

color, kidney damage, convulsions, allergic reactions and coma.

Please see Patient Package Insert for further information.

Therapeutic Target Organ(s) Not available

Not listed by OSHA, NTP or IARC.

**Potential Environmental Effects** There is no known ecological information for this product.

# 3. COMPOSITION/INFORMATION ON INGREDIENTS

Common Name	CAS-No	Composition
Antipyrine	60-80-0	4 - 4.5%

Common Name	CAS-No	Composition
Benzocaine	94-09-7	1 - 1.15%
Glycerine	56-81-5	94 - 95%
Oxyguinoline Sulfate	134-31-6	< 1%

## 4. FIRST AID MEASURES

Eye Contact In the case of contact with eyes, rinse immediately with plenty of water for 15 minutes and seek

medical advice.

Skin Contact Take off contaminated clothing and shoes immediately. Wash off immediately with soap and

plenty of water. If skin irritation persists, call a physician.

**Inhalation** Move to fresh air. Artificial respiration and/or oxygen may be necessary. If symptoms persist,

call a physician.

**Ingestion** If symptoms persist, call a physician. Do not induce vomiting without medical advice. Never

give anything by mouth to an unconscious person.

### 5. FIRE-FIGHTING MEASURES

Flammable Properties Not flammable.

**Extinguishing Media** 

Suitable Extinguishing Media

Unsuitable Extinguishing Media

Use water spray, foam, dry chemical or carbon dioxide.

Do NOT use water jet.

Fire Fighting Evacuate area and fight fire from a safe distance. Cool closed containers exposed to fire with

water spray. In the event of fire and/or explosion do not breathe fumes.

Hazardous Combustion Products Carbon oxides, nitrogen oxides.

Protective Equipment and Precautions for Firefighters

In the event of fire, wear self-contained breathing apparatus and special protective equipment

for fire fighters.

## 6. ACCIDENTAL RELEASE MEASURES

Personal Precautions Refer to protective measures listed in Sections 7 and 8.

Environmental Precautions Prevent product from entering drains. Local authorities should be advised if a significant spill

cannot be contained.

Methods for Containment Not available

Methods for Cleaning up Take up mechanically and collect in suitable container for disposal. Clean contaminated

surface thoroughly. Avoid formation of dust and aerosols.

### 7. HANDLING AND STORAGE

Handling For personal protection see Section 8. Handle in accordance with good industrial hygiene and

safety practice. Skin should be washed after contact. Avoid formation of dust and aerosols.

**Storage** No special safety precautions required. Keep container tightly closed.

## 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Common NameExposure GuidelineGlycerine10 mcg/m³ (ACGIH)Benzocaine500 mcg/m³AntipyrineNone assigned

Engineering Controls Apply technical measures to comply with the occupational exposure guideline. Local exhaust

ventilation is needed for limited open handling or where aerosols may be generated.

**Personal Protective Equipment** 

Eye/face ProtectionProvide eye protection based on risk assessment.Skin ProtectionWear nitrile or latex gloves. Wear protective garment.Respiratory ProtectionBase respirator selection on a risk assessment.

General Hygiene When using, do not eat, drink or smoke. General industrial hygiene practice. Wash hands

**Considerations** before breaks and at the end of workday.

Other Limit access to only personnel trained in the safe handling of this material Consult a health and

safety professional for specific PPE, respirator, and risk assessment guidance

## 9. PHYSICAL AND CHEMICAL PROPERTIES

**Physical State Appearance** Pharmaceutical Liquid Liquid Color Clear Odor Not available **Odor Threshold** Not available Molecular Formula Not applicable Not applicable Molecular Weight Not applicable **Specific Gravity** Not applicable **Water Solubility** Not applicable Not applicable Not applicable Solubility **Evaporation Rate** Not available Not applicable **Partition Coefficient** Vapor Pressure (n-octanol/water) **Boiling Point** Not applicable **Autoignition Temperature** Not applicable **Flash Point** Not applicable Method None **Melting Point** Not applicable **Flammability Limits Upper** Not applicable Lower Not applicable in Air **Explosion Limits Upper** Not applicable Lower Not applicable

## 10. STABILITY AND REACTIVITY

Chemical Stability Stable at room temperature.

Conditions to Avoid No data available

Materials to Avoid No materials to be especially mentioned.

Hazardous Decomposition Products None under normal use.

Possibility of Hazardous Reactions None under normal use.

## 11. TOXICOLOGICAL INFORMATION

The following effects are based on the Active Pharmaceutical Ingredient.

#### **Acute Toxicity**

**Antipyrine** 

LD50 Oral 1705 mg/kg rats, 1310 mg/kg mice

Acute Dermal Irritation No data available Primary Eye Irritation No data available Sensitization No data available

Benzocaine

**LD50 Oral** 3042 mg/kg rats

Acute Dermal Irritation Mild irritation effect in guinea pigs.

Primary Eye Irritation Not available Sensitization Not available

Glycerine

LD50 Oral 12.6 gm/kg rats, 4090 mg/kg mice
Acute Dermal Irritation Mild irritation effect in rabbits.

Primary Eye Irritation Irritating to rabbit eyes.

Sensitization Not available

**Multiple Dose Toxicity** 

**Antipyrine** 

No Toxicologic Effect No data available

Dose/Species/Study Length:

Benzocaine

No Toxicologic Effect No data available

Dose/Species/Study Length:

Glycerine

No Toxicologic Effect In a 180-day study in rats, 5% in drinking water caused calcification in the renal tubules. A

**Dose/Species/Study Length:** further drinking water study in rats resulted in increased urinary levels of oxalic acid.

Maximum Tolerated Dose (MTD), Oral

**Antipyrine** 

Carcinogenicity No data available
Genetic Toxicity No evidence of m

**Genetic Toxicity**No evidence of mutagenicity was observed in a battery of *in vitro* and *in vivo* assays.

Reproductive Toxicity
In a two-generation study in rats a slight decrease in body weight gain was observed in parents

and F<sub>2</sub> generation. No effects on fertility were observed in F<sub>1</sub> generation.

**Developmental Toxicity** Developmental toxicity studies in rats have been conducted in rats and rabbits. In rats, after

maternal toxic doses Fetotoxicity was evident including decreased body weight, food

consumption and motility, blood around nose and mouth, increased embryo/fetal mortality and anomalies of scaupla and ribs. In rabbits, although maternally toxic doses showed a decreased body weight in dams and increased embryotoxicity, no compound-related anomalies in fetuses

were observed.

Benzocaine

CarcinogenicityNo data availableGenetic ToxicityNo data availableReproductive ToxicityNo data availableDevelopmental ToxicityNo data available

**Glycerine** 

Carcinogenicity No data available

**Genetic Toxicity** Non-mutagenic in Ames test; non-clastogenic in chromosomal aberrations assay.

**Reproductive Toxicity** Studies in rats were found to have no effect on fertility.

Developmental Toxicity No teratogenic effects were observed in mice, rats and rabbits given large oral doses of >1

g/kg/day during pregnancy. In a further study, increased rates of embryonic and fetal death were seen when rats were dosed IV at 4 mg/kg; this was not seen in rabbit or mice studies.

**Antipyrine** 

Target Organ(s) of Toxicity No data available

Benzocaine

Target Organ(s) of Toxicity No data available

**Glycerine** 

Target Organ(s) of Toxicity No data available

## 12. ECOLOGICAL INFORMATION

The following effects are based on the Active Pharmaceutical Ingredient.

Chemical Fate Information Not available

**Ecotoxicity** Not available

### 13. DISPOSAL CONSIDERATIONS

Waste Disposal Method Dispose of in accordance with local and national regulations.

## 14. TRANSPORT INFORMATION

**Transport Information**This material is not classified as hazardous for transport.

U.S. Department of Transport (DOT)

Not regulated

Canadian Transport of Dangerous Goods (TDG)

International Civil Aviation Organization (ICAO)

International Air Transport Association (IATA)

International Maritime Dangerous Goods (IMDG)/International

Not regulated

Not regulated

**Maritime Organization (IMO)** 

Transport of Dangerous Goods by Rail (RID)

Not regulated Not regulated Transportation of Dangerous Goods via Inland Waterways

Not regulated Not regulated

(ADN)

## 15. REGULATORY INFORMATION

#### USA

## **Federal Regulations**

### **OSHA Regulatory Status**

This material is not considered hazardous by the OSHA Hazard Communication Standard (29 CFR 1910.1200)

#### **SARA 313**

Section 313 of Title III of the Superfund Amendments and Reauthorization Act of 1986 (SARA). This product does not contain any chemicals which are subject to the reporting requirements of the Act and Title 40n of the Code of Federal Regulations, Part 372.

#### SARA 311/312 Hazardous Categorization

Acute Health Hazard Yes
Chronic Health Hazard Yes
Fire Hazard No
Sudden Release of Pressure Hazard No
Reactive Hazard No

This product does not contain any HAPs.

## **State Regulations**

#### **California Proposition 65**

This product does not contain any Proposition 65 chemicals.

#### Canada

Not classified

## **WHMIS Hazard Class**

Non-controlled

#### **European Union**

In accordance with EC directives or respective national laws, the product does not need to be classified nor labeled.

### **16. OTHER INFORMATION**

Prepared By Wyeth Department of Environment, Health & Safety

Format This MSDS was prepared in accordance with ANSI Z400.1-2004.

**List of References** See Patient Package Insert for more information.

Revision Summary Not applicable

#### Disclaimer:

The information, data, recommendations, and suggestions appearing in this material safety data sheet (MSDS) and/or in materials regarding our active pharmaceutical ingredients (APIs) or products are based upon tests and data believed to be reliable as of the date of publication. NO REPRESENTATIONS OR WARRANTIES, EITHER EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR ANY OTHER WARRANTY IS MADE WITH REGARD TO THE INFORMATION PROVIDED IN THE MSDS, REGARDING THE API, OR THE PRODUCT TO WHICH THE INFORMATION PERTAINS. Accordingly, Wyeth will not be responsible for any damages resulting from use of, or reliance upon, this information as conditions of use are beyond our control. Users are responsible for assuring the safety of their workers and safe operating conditions, and for determining whether the API or product is suitable for their particular purposes. Users shall assume all risks of their use, handling, and disposal of the API and/or product in accordance with all appropriate and applicable regulations. This information relates only to the API or product designated herein, and does not relate to its use in combination with any other API, material, product, or process. No permission is granted for the use of any API or product in a manner that might infringe on existing patents.

**End of MSDS**